These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 14967493)

  • 21. Efficient human immunodeficiency virus ( HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate.
    Fang ZY; Kuli-Zade I; Spearman P
    J Infect Dis; 1999 Oct; 180(4):1122-32. PubMed ID: 10479139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.
    Liu F; Mboudjeka I; Shen S; Chou TH; Wang S; Ross TM; Lu S
    Vaccine; 2004 Apr; 22(13-14):1764-72. PubMed ID: 15068860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
    Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India.
    Kumar S; Aggarwal P; Vajpayee M; Pandey RM; Seth P
    Vaccine; 2006 Mar; 24(14):2585-93. PubMed ID: 16480792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.
    Liu Z; Chen YH
    J Immunol Methods; 2004 Feb; 285(1):93-7. PubMed ID: 14871538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression system.
    Pillay S; Meyers A; Williamson AL; Rybicki EP
    Biotechnol Prog; 2009; 25(4):1153-60. PubMed ID: 19572400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
    J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
    Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
    Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine.
    Wingard JB; Anderson B; Weissman D
    Eur J Immunol; 2008 May; 38(5):1310-20. PubMed ID: 18412164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.
    McGettigan JP; Naper K; Orenstein J; Koser M; McKenna PM; Schnell MJ
    J Virol; 2003 Oct; 77(20):10889-99. PubMed ID: 14512539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice.
    Egan MA; Megati S; Roopchand V; Garcia-Hand D; Luckay A; Chong SY; Rosati M; Sackitey S; Weiner DB; Felber BK; Pavlakis GN; Israel ZR; Eldridge JH; Sidhu MK
    Vaccine; 2006 May; 24(21):4510-23. PubMed ID: 16140439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits.
    Pal R; Yu Q; Wang S; Kalyanaraman VS; Nair BC; Hudacik L; Whitney S; Keen T; Hung CL; Hocker L; Kennedy JS; Markham P; Lu S
    Vaccine; 2006 Feb; 24(8):1225-34. PubMed ID: 16219399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immune response induced by HIV DNA vaccine combined with recombinant adeno-associated virus].
    Liu YZ; Zhou L; Wang Q; Ye SQ; Li HX; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):251-4. PubMed ID: 15640860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques.
    Amara RR; Sharma S; Patel M; Smith JM; Chennareddi L; Herndon JG; Robinson HL
    Virology; 2005 Mar; 334(1):124-33. PubMed ID: 15749128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prime-boost strategies in DNA vaccines.
    Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
    Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine.
    Wang S; Farfan-Arribas DJ; Shen S; Chou TH; Hirsch A; He F; Lu S
    Vaccine; 2006 May; 24(21):4531-40. PubMed ID: 16140431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells.
    Radaelli A; Bonduelle O; Beggio P; Mahe B; Pozzi E; Elli V; Paganini M; Zanotto C; De Giuli Morghen C; Combadière B
    Vaccine; 2007 Mar; 25(11):2128-38. PubMed ID: 17241705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.